ClinVar Miner

Submissions for variant NM_001042492.3(NF1):c.3274G>C (p.Gly1092Arg)

dbSNP: rs1457169236
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV002434396 SCV001180940 uncertain significance Hereditary cancer-predisposing syndrome; Cardiovascular phenotype 2019-03-15 criteria provided, single submitter clinical testing The p.G1092R variant (also known as c.3274G>C), located in coding exon 25 of the NF1 gene, results from a G to C substitution at nucleotide position 3274. The glycine at codon 1092 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Invitae RCV001860948 SCV002277262 uncertain significance Neurofibromatosis, type 1 2021-06-28 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt NF1 protein function. This variant has not been reported in the literature in individuals with NF1-related conditions. ClinVar contains an entry for this variant (Variation ID: 823372). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with arginine at codon 1092 of the NF1 protein (p.Gly1092Arg). The glycine residue is moderately conserved and there is a moderate physicochemical difference between glycine and arginine.
Genome-Nilou Lab RCV001860948 SCV002560280 uncertain significance Neurofibromatosis, type 1 2022-03-15 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.